MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

Zanubrutinib shows sustained efficacy and safety in relapsed/refractory CLL, with a median progression-free survival of 52.5 months in long-term follow-up.

Pirtobrutinib showed noninferiority in ORR compared to ibrutinib in BTK inhibitor-naive CLL/SLL patients, with a favorable PFS trend. Safety profiles indicated fewer adverse events with pirtobrutinib, ...

Regarding safety, any-grade adverse events occurred in 100% and 99% of patients on epcoritamab plus R 2 and R 2 alone, with grade 3 or higher AEs at 90% and 68%, respectively. Serious AEs occurred in ...

Azacitidine plus venetoclax (Venclexta) demonstrated significantly improved event-free survival (EFS) vs intensive induction chemotherapy in patients with acute myeloid leukemia (AML), according to ...

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...

Gintemetostat showed promising activity in heavily pretreated, triple-class refractory multiple myeloma, including high-risk t(4;14) patients. The phase 1 study reported a tolerable safety profile, ...

Outcomes at one year demonstrated that high-degree mismatching did not adversely affect patient survival when PTCy was ...

Epcoritamab combined with R-mini-CHOP showed a 93% overall response rate in elderly DLBCL patients, with 86% achieving complete response. At two years, 79% of patients remained in response, and 90% ...

KRd regimen significantly improved PFS over VRd in newly diagnosed multiple myeloma, reducing progression or death risk by 43%. Consistent benefits of KRd were observed across cytogenetic subgroups, ...

Lisocabtagene maraleucel is the first CAR T-cell therapy approved for relapsed or refractory MZL, expanding treatment options ...